CP-064 Comparative efficacy of biological drugs in the maintenance phase in adult patients with moderate-severe plaque psoriasis

The aim of the study was to assess clinical and economic effectiveness of netakimab compared to other genetically engineered biologic drugs (infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, certolizumab pegol) for the treatment of adult patients with moderate to severe plaque psoriasis. We have conducted cost-benefit analysis, cost-minimisation analysis, and budget impact analysis. We have considered only direct medical costs. The results of the study show that netakimab has higher or comparable efficacy and significantly lower costs compared to other biologic drugs, that makes it the most preferable treatment option for patients with moderate to severe plaque psoriasis. Use of netakimab in clinical practice will significantly reduce budget expenditures and increase patient access to biologic therapy.

Download Full-text

PBI3 Comparative Efficacy of Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis

Value in Health ◽

10.1016/j.jval.2021.04.074 ◽

2021 ◽

Vol 24 ◽

pp. S14

Author(s):

A. Armstrong ◽

K. Reich ◽

R.B. Warren ◽

V. Taieb ◽

K. Fahrbach ◽

...

Keyword(s):

Plaque Psoriasis ◽

Meta Analysis ◽

Comparative Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

25030 Comparative efficacy of treatments for moderate-to-severe plaque psoriasis: An updated network meta-analysis (NMA)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.041 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB4

Author(s):

April W. Armstrong ◽

Ahmed M. Soliman ◽

Lluís Puig ◽

Keith A. Betts ◽

Yan Wang ◽

...

Keyword(s):

Plaque Psoriasis ◽

Meta Analysis ◽

Comparative Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Pilot Study to Evaluate the Efficacy and Safety of Oral Tacrolimus in Adult Patients With Refractory Severe Plaque Psoriasis

Journal of Cutaneous Medicine and Surgery ◽

10.1177/1203475415616964 ◽

2015 ◽

Vol 20 (3) ◽

pp. 228-232 ◽

Cited By ~ 1

Author(s):

Ankit Mittal ◽

Sunil Dogra ◽

Tarun Narang ◽

Aman Sharma

Keyword(s):

Pilot Study ◽

Plaque Psoriasis ◽

Severity Index ◽

Term Treatment ◽

Adult Patients ◽

Efficacy And Safety ◽

Open Label ◽

Short Term Treatment ◽

Psoriasis Area Severity Index ◽

Severe Plaque Psoriasis

Background: Tacrolimus, a congener of cyclosporine, has replaced cyclosporine as a first-line treatment for most transplant patients due to its superior efficacy and safety. Tacrolimus has not been extensively studied for the treatment of psoriasis. Objectives: To study the efficacy and safety of oral tacrolimus in adult patients with severe refractory plaque psoriasis. Methods: This was an open-label pilot study. Patients with severe plaque type psoriasis who were unresponsive to at least 1 systemic treatment were treated with oral tacrolimus. Results: Thirty patients were treated. After 12 weeks, improvement in mean Psoriasis Area Severity Index (PASI) score was 80.37% ( P < .001), PASI 75 was observed in 19 of 26 (73.1%) patients, and PASI 90 was observed in 11 of 26 (42.3%) patients. No severe side effects were noted. Conclusion: Oral tacrolimus is an effective and safe option for the short-term treatment of severe plaque psoriasis.

Download Full-text